Skip to main content

Advertisement

SpringerLink
Log in

The Relationship of the BRAFV600E Mutation and the Established Prognostic Factors in Papillary Thyroid Carcinomas

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

It has been shown that BRAFV600E mutation in papillary thyroid carcinomas (PTC) is associated both with pathogenesis and poor prognosis. In this study, we aimed to investigate the relationship of the BRAFV600E mutation and the established prognostic factors in a cohort of Turkish patients with PTC. Forty-six cases of papillary thyroid carcinoma have been evaluated for the presence of BRAFV600E mutation. BRAFV600E has been examined by restriction fragment length polymorphism. BRAFV600E mutation status has been compared with well-known histopathological and clinical prognostic parameters such as invasion of thyroid capsule, extrathyroidal extension, and the presence of lymph node and/or distant metastasis. We have found that BRAFV600E mutation was present in the majority of our cases (40/46). Considering the stage of the disease, five of the negative cases were in stage 1 while the remaining one was in stage 2. Only one BRAFV600E negative case has shown extrathyroidal extension and lymph node metastasis. All four patients with distant metastasis had BRAFV600E mutation. Statistical analyses revealed that there are no significant relationship between the BRAFV600E mutation and the established prognostic factors. We found a relatively higher BRAFV600E mutation rate in classical type PTC than in other similar studies. We think that the limited number of our cases may either weaken or mask some potentially important relationship between BRAFV600E mutation and the established prognostic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jameson JL, Weetman AP: Disorders of the thyroid gland. Harrison's Principles of Internal Medicine, eds: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. The McGraw Hill Companies, New York pp: 2014, 2005.

    Google Scholar 

  2. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA, BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 93, 2194–2201, 2008.

    Article  PubMed  CAS  Google Scholar 

  3. Kondo T, Nakazawa T, Murata S et al: Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol. 38(12), 1810–1818, 2007.

    Article  PubMed  CAS  Google Scholar 

  4. Chakraborty A, Narkar A, Mukhopadhyaya R et al: BRAF (V600E) Mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal ınvasion. Endocr Pathol. 22, 132–136, 2012.

    Google Scholar 

  5. Martur A, Moses W, Rahbari R et al: Higher rate of BRAF mutation in papillary thyroid cancer over time. Cancer. 117, 4390–4395, 2011.

    Article  Google Scholar 

  6. Ito Y, Yoshida H, Maruo R et al: BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 56(1), 89–97, 2009.

    Article  PubMed  CAS  Google Scholar 

  7. Jo YS, Huang S, Kim YJ et al: Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf). 70, 139–144, 2009.

    Article  CAS  Google Scholar 

  8. Salerno P, Falco VD, Tamburino A et al: Cytocytatic activity os ATP-competetive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 95, 450–455, 2009.

    Article  PubMed  Google Scholar 

  9. Kim TY, Kim WB, Song JY et al; The BRAF mutation is not associated with prognostic factors in Korean patients with conventional papillary microcarcinomas. Clin Endocrinol Oxf. 63, 588–593, 2009.

    Article  Google Scholar 

  10. Mingzhao Xing: Prognostic utulity of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 321, 86–93, 2011.

    Google Scholar 

  11. O’neill CJ, Bullock M, Chou A et al: BRAF V600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 148, 1139–1146, 2010.

    Article  PubMed  Google Scholar 

  12. Frasca F, Nucera C, Pellegriti G et al: BRAF V600E mutation and biology of papillary thyroid cancer. Endocr Relat Cancer 15, 191–205, 2008.

    Article  PubMed  CAS  Google Scholar 

  13. Ball DW: Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab. 95(1), 60–61, 2010.

    Article  PubMed  CAS  Google Scholar 

  14. Howell GM, Carty SE, Armstrong MJ et al: Both BRAF V600E Mutation and older age (>65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 18(13), 3566–3571, 2011.

    Article  PubMed  Google Scholar 

  15. Kim TH, Park YJ, Lim JA et al: The association of the BRAF V600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. A meta analysis. Cancer. 31, 343–347, 2011.

    Google Scholar 

  16. Nam JK, Jung CK, Song BJ et al: Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer. Am J Surg. 29, 873–879, 2011.

    Google Scholar 

  17. Ozturk M, Oter S. Molecular approach to treatment of hepatocellular carcinoma: new hope for therapeutic targets. J Exp Integr Med. 1(2), 83–84, 2011.

    Article  Google Scholar 

  18. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature. Jan 19;439(7074), 358–362, 2006.

    Article  PubMed  CAS  Google Scholar 

  19. Lanthaler AJ, Spizzo G, Mitterer M et al: Interlaboratory comparison of K-ras testing by real-time PCR and RFLP in colorectal cancer samplesDiagn Mol Pathol. 2011 Jun;20(2):90–3.

    Article  PubMed  Google Scholar 

  20. Zatelli MC, Trasforini G, Leoni S et al: BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol.161, 467–473, 2009.

    Article  PubMed  CAS  Google Scholar 

  21. Kucukodaci Z, Akar E, Haholu A, Baloglu H. A valuable adjunct to FNA diagnosis of papillary thyroid carcinoma: in-house PCR assay for BRAF T1799A (V600E). Diagn Cytopathol. Jun;39(6), 424–427, 2011.

    Article  PubMed  Google Scholar 

  22. Adrienne LM, Linwah Y, Sally EC: The utility of BRAF testing in the menagement of papillary thyroid cancer. Oncologist. 15, 1285–1293, 2010.

    Article  Google Scholar 

Download references

Acknowledgments

The authors would like to thank to Scientific and Technological Research Council of Turkey (TÜBITAK) for their support (Grant No: 19816). We also would like to express our sincere appreciation to FAVOR (FMF Arthritis Vasculitis and Orphan Diseases Research) laboratories at Gülhane Military Medical Academy, Institute of Health Sciences for their supports in conducting the experiments and invaluable guidance for the preparation of the manuscript.

Author information

Authors and Affiliations

  1. Department of Pathology, Gülhane Military Medical Academy and School of Medicine, 06018, Etlik, Ankara, Turkey

    Bülent Kurt, Yıldırım Karslıoğlu, Nuri Yigit, Armağan Günal & M. Salih Deveci

  2. Kaman Vocational School, Ahi Evran University, Kırıkkale, Turkey

    Serap Yalçın

  3. Department of Nuclear Medicine, Gülhane Military Medical Academy and School of Medicine, 06018, Etlik, Ankara, Turkey

    Engin Alagöz

  4. Department of Pathology, Gülhane Military Medical Academy and Medical School, 06018, Etlik, Ankara, Turkey

    Bülent Kurt

Authors
  1. Bülent Kurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serap Yalçın
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Engin Alagöz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yıldırım Karslıoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nuri Yigit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Armağan Günal
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Salih Deveci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bülent Kurt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurt, B., Yalçın, S., Alagöz, E. et al. The Relationship of the BRAFV600E Mutation and the Established Prognostic Factors in Papillary Thyroid Carcinomas. Endocr Pathol 23, 135–140 (2012). https://doi.org/10.1007/s12022-012-9218-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-012-9218-7

Keywords

Search

Navigation